The federal government’s new plan to rescue medical devices from regulatory limbo comes with a hidden catch that could leave many innovators behind.

Federal regulators are closing the fast track to extra Medicare funding, forcing medical device makers to prove real clinical value rather than relying on a prestigious FDA label.